Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™

PHASE3CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

November 30, 2009

Conditions
Hepatitis B
Interventions
BIOLOGICAL

Henogen HB vaccine

Month 12, 24 and 36

BIOLOGICAL

Fendrix vaccine

Month 12, 24 and 36

Trial Locations (23)

1020

CHU Brugmann (site V Horta) Service de néphrologie, Brussels

1070

ULB Hôpital Erasme Département de Néphrologie, Brussels

1085

St. Rókus Hospital, Budapest

1090

AZ -VUB Dienst Nefrologie, Brussels

1096

St. István Hospital, Budapest

1200

Cliniques universitaires Saint Luc, Brussels

2143

Pest County Flór Ferenc Hospital, Kistarcsa

3000

UZ Gasthuisberg Leuven Nierziekten, Leuven

6000

CHU Hôpital civil de, Charleroi

6110

CHU Andre VESALE, Montigny-le-Tilleul

7100

CHU Tivoli, La Louvière

7331

RHMS Clinique Louis Caty Baudour, Baudour

7500

RHMS TournayService de néphrologie, Tournai

7800

RHMS La Madeleine ATH, Ath

9000

UZ Gent, Ghent

9023

Petz Aladár Teaching Hospital, Győr

9300

O.L.Vrouwziekenhuis Aalst, Aalst

9700

Vas and Szombathely County Markusovszky Hospital, Szombathely

46063

Regional Hospital Liberec, Liberec

59586 33

Hospital JihlavaVrchlického, Jihlava

708 52

University Hospital with Outpatient Clinic Ostrava, Ostrava

169 00

Dept. of Internal Medicine StrahovSermirska 5, Prague

401 13

Masaryk´s Hospital Socialni pece 3316/12A, Ústí nad Labem

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Henogen

INDUSTRY

NCT00445185 - Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™ | Biotech Hunter | Biotech Hunter